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stem cells, and methods of implantation that need to be evaluated 
clinically to determine the optimal method for cartilage regeneration 
and restoration of the articular environment.
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29.1
Enhanced autologous one-stage procedure for cartilage 
regeneration
B.A. Byers, J.J. Hwang, Y. Lu, S. Dhanaraj, J. Geesin, and F. Binette,
United States of America 
Articular cartilage exhibits limited intrinsic repair capacity due 
to the relatively acellular, avascular, and non-innervated nature 
PG UIF UJTTVF DPVQMFE XJUI UIF EFOTF ¾CSJMMBS BSDIJUFDUVSF PG UIF
extracellular matrix that restricts outward migration of embedded 
chondrocytes. Multiple clinical strategies have been explored to 
enhance cartilage repair, including those categorized as either one-
stage (point-of-care) or two-stage procedures. Current single-step 
techniques, including lavage and debridement, microfracture, and 
mosaicplasty, while serving to reduce pain and symptoms, present 
TJHOJ¾DBOUDIBMMFOHFTGPSMPOHUFSNGVODUJPO.JDSPGSBDUVSFPSCPOF
marrow stimulation is the current treatment of choice for small, 
contained lesions and exhibits relatively good clinical outcomes 
with controlled technique and regimented rehabilitation (Miller et 
al. J Knee Surg. 2004). However, it may have suboptimal outcomes 
in patients with larger defects or for those who fail to follow a strict 
SFIBCJMJUBUJPO QSPHSBN 5IF SFTVMUBOU ¾CSPDBSUJMBHFOPVT SFQBJS
tissue derived from microfracture may exhibit inferior tolerance to 
long-term biomechanical loading as compared to normal hyaline 
cartilage. 
In an effort to achieve repair tissue that is more hyaline in nature, 
two-stage cell-based techniques, including autologous chondrocyte 
implantation (ACI) and matrix-induced ACI, have been explored. 
These strategies require an initial cartilage biopsy, ex vivo cell 
expansion of the isolated chondrocytes, and a second surgery to 
SFQBJSUIFEFGFDU8IJMFFG¾DBDJPVTSFQBJSIBTCFFOEFUBJMFEJOSFDFOU
clinical reports (Peterson et al. J Bone Joint Surg 2003; Mandelbaum 
et al. Am J Sports Med 2007), there has yet to be broad-based 
clinical acceptance of these two-step therapeutic approaches. 
5IFNPTU TJHOJ¾DBOU MJNJUBUJPOTPG UXPTUFQ TUSBUFHJFT JOWPMWF UIF
patient’s exposure to multiple procedures as well as the time and 
cost associated with ex vivo cell expansion and/or cell-scaffold 
preparation. Additionally, reduction in chondrogenic potency due 
to passage-dependent dedifferentiation of primary chondrocytes 
may impact the quality of tissue generated at the defect site. Finally, 
IBSWFTUJOH BOE TVUVSJOH UIF QFSJPTUFBM ¿BQ JOUSPEVDFT DPNQMFYJUZ
and adds surgical time.
To overcome the challenges associated with current cartilage repair 
solutions, we have developed the Cartilage Autograft Implantation 
System (CAIS), a point-of-care therapy combining mechanically 
fragmented autologous cartilage seeded on a bioresorbable scaffold. 
4QFDJ¾DBMMZ UIJTPOFTUBHFBQQSPBDINPSTFMJ[FTEPOPS UJTTVF UIF
same quantity required for ACI, into small fragments that preserves 
cell viability and promotes cellular outgrowth. These tissue fragments 
BSFTFFEFEPOBUISFFEJNFOTJPOBMTDBGGPMEUIBUQSPWJEFTBEF¾OFE
architecture to support cell outgrowth, proliferation, and subsequent 
NBUSJYEFQPTJUJPO5IFDPNQPTJUFHSBGUJTUIFOSJHJEMZBG¾YFEJOBGVMM
thickness cartilage defect using bioresorbable staples. In addition 
to the cellular and scaffold components of CAIS, minced cartilage 
fragments transplanted in the repair site contain a repository of 
matrix-embedded growth factors (Erlacher et al. Arth Rheum 1998). 
As the cartilage fragments are resorbed during the repair process, it 
is possible that these embedded growth factors are released from 
their matrix and provide endogenous prochondrogenic stimuli at the 
site of repair. 
In vitro studies have demonstrated maintenance of chondrocyte 
viability as well as time-dependent cellular outgrowth into the 
CAIS scaffold following tissue fragmentation. In a heterotopic 
model, outgrowth cells exhibit more robust neo-cartilagenous 
tissue formation than subculture-expanded chondrocytes, as 
revealed by Safranin-O staining. These observations suggest that 
chondrocytes outgrown from minced cartilage fragments may 
retain their differentiated chondrocytic phenotype by avoiding the 
environmental trauma associated with ex vivo culture, including 
enzymatic isolation, exposure to animal bi-products in the cell 
culture media, and extensive passaging in monolayer culture. 
Large animal models implementing this one-stage technique 
for repair of critical-size, full thickness chondral defects have 
demonstrated hyaline-like tissue repair that is well integrated with 
adjacent cartilage and subchondral bone as early as 6 months post-
surgery. Additionally, results from a 12-month equine study suggest 
this one-step approach may provide similar or improved healing 
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QSPHSFTTJPOBOEIZBMJOFMJLFUJTTVFSFQBJSDPNQBSFEUPBNPEJ¾FE
ACI technique. Human clinical studies evaluating the safety of CAIS 
are currently ongoing.
Exogenous growth factors, such as members of the TGF-  superfamily, 
could be co-delivered with the minced cartilage fragments to further 
stimulate or accelerate the production of cartilagenous matrix by 
the outgrown chondrocytes. We have explored the prochondrogenic 
potential of recombinant human Growth and Differentiation Factor 
5 (rhGDF-5) to enhance cartilage matrix production of both isolated 
chondrocytes in vitro and minced cartilage fragments in a heterotopic 
model. In both systems, a robust, dose-dependent enhancement of 
neo-cartilagenous tissue formation was observed following rhGDF-5 
treatment, suggesting that this combined cell-biologic therapeutic 
strategy may further improve chondral defect repair.
CAIS, a one-stage cartilage regeneration therapy, offers many 
practical advantages compared to other cell-based techniques. 
Delivery of minced cartilage provides a direct source of primary, 
autologous chondrocytes to the site of repair as opposed to 
marrow-derived cells arising from microfracture procedures. These 
minced cartilage-derived chondrocytes subsequently outgrow and 
proliferate in situ, obviating the need for ex vivo cell expansion and 
thus eliminating the associated costs and safety concerns. Further, 
as minced cartilage-derived chondrocytes are not subjected to ex 
vivo culture, it is possible they may retain a more natural or even 
more potent chondrogenic phenotype than culture-expanded cells. 
.PTUJNQPSUBOUMZ$"*4JTB¾STUMJOFDBSUJMBHFSFHFOFSBUJPOUIFSBQZ
to provide intra-operative treatment immediately upon diagnosis 
EVSJOHUIF¾STUBSUISPTDPQZ UIFSFCZ MJNJUJOHUIFQBUJFOUµTTVSHJDBM
regimen to a single procedure.
29.2
Cellular synergy for 1 step cartilage repair 
J. Hendriks, E. de Bruijn, R. Schotel, C.A. van Blitterswijk, J. Riesle,
Netherlands
One of the current treatments for cartilage defects is based on expanded 
chondrocytes (ACI). Expansion of chondrocytes is, however, expensive, 
requires a complicated procedure including 2 surgeries, and hampers 
cellular quality as it results in cell dedifferentiation. This has prevented 
widespread acceptance of this treatment. We previously established 
a synergetic effect of a combination of primary chondrocytes with 
expanded chondrocytes to substantially enhance cartilage formation 
compared to expanded chondrocytes (Hendriks et al, 2005). To address 
the drawbacks of ACI, we hypothesized that primary chondrocytes 
and bone marrow cells synergize in cartilage formation. We further 
hypothesized that the required number of primary chondrocytes can 
be isolated from a small biopsy within surgery time. Together with an 
intra-operative source for bone marrow cells, a simple one surgery 
treatment for cartilage defects may be developed. The aim of this 
study was to investigate i) if a combination of primary chondrocytes 
and bone marrow cells synergize in enhancing cartilage formation, 
compared to expanded chondrocytes, in vitro and in vivo, and, ii) to 
establish chondrocyte isolation within less then an hour. 
'PSUIF¾STUJOWJUSPTUVEZXFDPNCJOFEIVNBOQSJNBSZDIPOESPDZUFT
and human expanded bone marrow cells at various ratios into micromass 
pellets, cultivated in standard medium without growth factors for 2 
weeks, and analyzed for glycosaminoglycans (GAG), histologically and 
biochemically. Average chondrocyte and bone marrow donor age was 
69 years (range 47-78) and 42 years (range 24-55), respectively. For 
the in vivo study, we combined bovine or human primary chondrocytes 
and human expanded bone marrow cells, seeded them into PEGT/PBT 
polymer scaffolds, implanted into nude mice, and analyzed for GAG and 
collagen type II eight weeks post-implantation. For the second study, 
we dissected human cartilage, enzymatically digested for various 
timeperiods, and analyzed for cell number and viability. 
In vitro results showed that micromass pellets comprising 20% primary 
DIPOESPDZUFTBOECPOFNBSSPXDFMMTDPOUBJOTJHOJ¾DBOUMZNPSF
GAG compared to the expanded chondrocyte and bone marrow 
DPOUSPMTBOEBDPNQBSBCMF	OPUTJHOJ¾DBOUMZEJGGFSFOU
BNPVOUPG("(
DPNQBSFE UP UIF QSJNBSZ DIPOESPDZUF DPOUSPM 5IFTF¾OEJOHT
were in agreement with safranin O histologies; we detected positive 
staining for the cell combination groups, and negative staining for 
the expanded chondrocyte and bone marrow controls. GAG content 
per added primary chondrocytes increased on average 3 fold for the 
10%/90% chondrocyte/bone marrow combination group, compared to 
the 100% primary chondrocyte control. In vivo results were consistent 
with in vitro results. Moreover, collagen type II staining was positive, 
and GAG content per added primary chondrocytes increased 7 fold (for 
a 10%/90% ratio), compared to the 100% primary chondrocyte group. 
Interestingly, GAG per added primary chondrocytes increased with 
decreasing added chondrocyte content, for both in vitro and in vivo 
studies. A substantial chondrocyte number could be isolated within 
10-30 min from cartilage of donors of an average age of 69 years (rage 
47-83). 
We have demonstrated a combination of primary chondrocytes and bone 
marrow cells to synergize in enhancing cartilage formation, compared to 
expanded chondrocytes, in vitro and in vivo. We further demonstrated 
an increased GAG content per added primary chondrocytes for the 
cellular synergy system compared to primary chondrocytes alone. 
Finally, we have established chondrocyte isolation within less then 
BOIPVS1SPWJEFEUIFTF¾OEJOHDBOCFWFSJ¾FEGPSBDPNCJOBUJPOPG
chondrocytes with non expanded bone marrow cells, cellular synergy 
provides the basis for a one surgery cartilage defect treatment without 
the need for cell culture expansion, comprising: cartilage and bone 
marrow harvest, chondrocyte isolation, cell combination, seeding of 
the cell combination into a biomaterial scaffold, and, implantation. 
Further studies will be required to understand the mechanism of 
cellular synergy. Enhancement of chondrogenesis may depend on, 
either, i) chondrocytes instructing bone marrow cells to undergo 
chondrogenesis, ii) bone marrow cells enhancing chondrogenesis of 
chondrocytes, or iii) a combination of the two. Regardless of the exact 
mechanism, the potency of the cellular synergy system forms a highly 
suitable basis to advance the effectiveness of current cartilage repair. 
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